First Atom Therapeutics

CompanyUnited States

First Atom Therapeutics develops 2 assets, the furthest preclinical (ATX-091 in ischemia/stroke). Mostly small molecule acting on SARM1; based in the United States.

2
Assets
Furthest stage: Preclinical; 0
Trials: 0
Signals

Pipeline

ATX-091
Inhibits DRP1, targeting mitochondrial fragmentation.
Preclinical, Small molecule, ischemia/stroke, Parkinson's disease
ATX-624
Allosterically inhibits SARM1 by gluing two protein domains together, stabilizing its inactive structure.
Preclinical, Small molecule, SARM1, ADOA, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms1
People19
Similar companies6